← Leaderboards
Joanna B. Goldberg
University Of Virginia Charlottesville
$11,938,433
Attributed
$12,234,575
Total exposure
19
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,234,575 · 19
By mechanism
R01$7,345,359 · 6
R21$4,548,910 · 11
T32$337,806 · 1
R13$2,500 · 1
Top collaborators
- Graeme L Conn1 shared
- David Elihu Greenberg1 shared
Others in their field
Top investigators on “Pseudomonas Aeruginosa”
- Henry F Chambers · Duke University$46,515,637
- Vance G Fowler · Duke University$46,515,637
- Deborah T Hung · Massachusetts General Hospital$24,051,776
- Ryan Cirz · Revagenix, Inc.$22,711,751
- Daniel J Wozniak · Ohio State University$19,184,613
- Alan R Hauser · Northwestern University$18,516,245
Research focus
Pseudomonas AeruginosaLipopolysaccharidesInfectionPathogenLifeMouse ModelBacteriaGrantChronicLungCystic FibrosisGenesVirulenceCystic Fibrosis PatientsMutantAcutePneumoniaSurfaceProteinsImmunocompromised HostVaccinesAntigensAntibiotic ResistanceEnvironment
Grant awards (44)
Monoclonal Antibody to Combat Pseudomonas Aeruginosa$656,358
R01 · FY2025 · AI · contact PI
Antimicrobial Resistance and Therapeutic Discovery Training Program$337,806
T32 · FY2025 · AI
Identifying Mechanisms of Resistance to Pathogen-Specific Antibacterial Antisense Compounds and Strategies to Circumvent Them$254,478
R21 · FY2025 · AI
Monoclonal Antibody to Combat Pseudomonas Aeruginosa$968,643
R01 · FY2024 · AI · contact PI
Pyocins as antibacterials to treat Pseudomonas aeruginosa infections$238,569
R21 · FY2024 · AI · contact PI
Monoclonal Antibody to Combat Pseudomonas Aeruginosa$1,021,806
R01 · FY2023 · AI · contact PI
Pyocins as antibacterials to treat Pseudomonas aeruginosa infections$219,891
R21 · FY2023 · AI · contact PI
Mechanisms of Staphylococcus aureus and Pseudomonas aeruginosa Co-existence in CF$229,499
R21 · FY2021 · AI · contact PI
Regulation of Pseudomonas aeruginosa Virulence Gene Expression by Temperature$230,279
R21 · FY2020 · EY · contact PI
Mechanisms of Staphylococcus aureus and Pseudomonas aeruginosa Co-existence in CF$190,908
R21 · FY2020 · AI · contact PI
Regulation of Pseudomonas aeruginosa Virulence Gene Expression by Temperature$191,618
R21 · FY2019 · EY · contact PI
Impact of Alginate Overproduction on P. aeruginosa LPS O Antigen Expression$231,205
R21 · FY2018 · AI · contact PI
Impact of Alginate Overproduction on P. aeruginosa LPS O Antigen Expression$192,459
R21 · FY2017 · AI · contact PI
Mechanism of Phosphorylcholination of EF-Tu on Pseudomonas aeruginosa$192,900
R21 · FY2015 · AI · contact PI
Mechanism of Phosphorylcholination of EF-Tu on Pseudomonas aeruginosa$231,900
R21 · FY2014 · AI · contact PI
Virulence Determinants for Host Tropism in the Burkholderia cepacia complex$195,682
R21 · FY2014 · AI · contact PI
Virulence Determinants for Host Tropism in the Burkholderia cepacia complex$233,867
R21 · FY2013 · AI · contact PI
Purine biosynthesis as a therapeutic target for Helicobacter pylori infection$219,960
R21 · FY2013 · AI · contact PI
Purine biosynthesis as a therapeutic target for Helicobacter pylori infection$108,286
R21 · FY2012 · AI · contact PI
Purine biosynthesis as a therapeutic target for Helicobacter pylori infection$88,797
R21 · FY2012 · AI · contact PI
Live Attenuated Recombinant Bacterial Delivery of Polysaccharide Vaccine Antigens$355,258
R01 · FY2010 · AI · contact PI
Role of Burkholderia Cenocepacia Adhesin, AdhA, in Cystic Fibrosis Infections$222,242
R21 · FY2010 · AI · contact PI
Live Attenuated Recombinant Bacterial Delivery of Polysaccharide Vaccine Antigens$134,702
R01 · FY2010 · AI · contact PI
Live Attenuated Recombinant Bacterial Delivery of Polysaccharide Vaccine Antigens$358,902
R01 · FY2009 · AI · contact PI
Role of Burkholderia Cenocepacia Adhesin, AdhA, in Cystic Fibrosis Infections$199,497
R21 · FY2009 · AI · contact PI
Live Attenuated Recombinant Bacterial Delivery of Polysaccharide Vaccine Antigens$358,958
R01 · FY2008 · AI · contact PI
Novel Recombinant Vaccines to Protect Against Burkholderia Infections$226,380
R21 · FY2008 · AI · contact PI
Live Attenuated Recombinant Bacterial Delivery of Polysaccharide Vaccine Antigens$365,964
R01 · FY2007 · AI · contact PI
Novel Recombinant Vaccines to Protect Against Burkholderia Infections$194,493
R21 · FY2007 · AI · contact PI
Live Attenuated Recombinant Bacterial Delivery of Polysaccharide Vaccine Antigens$377,153
R01 · FY2006 · AI · contact PI
Helicobacter pylori LPS Signaling and Role in Chronicity$331,758
R01 · FY2005 · AI
Helicobacter pylori LPS Signaling and Role in Chronicity$331,806
R01 · FY2004 · AI
Synthesis of P.Aeruginosa LPS and its Role in Infection$241,410
R01 · FY2004 · AI
Pseudomonas aeruginasa LPS: A Post-Genomic Analysis$228,000
R21 · FY2004 · AI
Helicobacter pylori LPS Signaling and Role in Chronicity$331,852
R01 · FY2003 · AI
Synthesis of P.Aeruginosa LPS and its Role in Infection$241,410
R01 · FY2003 · AI
Pseudomonas aeruginasa LPS: A Post-Genomic Analysis$228,000
R21 · FY2003 · AI
Helicobacter pylori LPS Signaling and Role in Chronicity$319,896
R01 · FY2002 · AI
Synthesis of P.Aeruginosa LPS and its Role in Infection$202,560
R01 · FY2002 · AI
Synthesis of P.Aeruginosa LPS and its Role in Infection$250,147
R01 · FY2001 · AI
PSEUDOMONAS AERUGINOSA LPS CORE AND PATHOGENESIS$176,478
R01 · FY2001 · AI
PSEUDOMONAS AERUGINOSA LPS CORE AND PATHOGENESIS$171,337
R01 · FY2000 · AI
LEWIS ANTIGEN EXPRESSION AND PATHOGENESIS OF H PYORI$148,961
R01 · FY2000 · AI
FASEB SUMMER CONFERENCE--MICROBIAL POLYSACCHARIDES$2,500
R13 · FY2000 · DE